{"id":"https://openalex.org/W4396590940","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po3-13-11","title":"Abstract PO3-13-11: Quantitative Multiplex Immunofluorescence Assay for TROP2 and HER2 Expression in Breast Cancer: Towards Guiding Patient Selection for Antibody Drug Conjugate Therapies","display_name":"Abstract PO3-13-11: Quantitative Multiplex Immunofluorescence Assay for TROP2 and HER2 Expression in Breast Cancer: Towards Guiding Patient Selection for Antibody Drug Conjugate Therapies","publication_year":2024,"publication_date":"2024-05-02","ids":{"openalex":"https://openalex.org/W4396590940","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po3-13-11"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs23-po3-13-11","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po3-13-11","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs23-po3-13-11","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Charles Robbins","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles Robbins","raw_affiliation_strings":["1Yale,","Yale,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Yale,","institution_ids":["https://openalex.org/I32971472"]},{"raw_affiliation_string":"Yale,","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104186042","display_name":"Mengni He","orcid":"https://orcid.org/0000-0003-4228-4462","observed_orcids":["https://orcid.org/0000-0003-4228-4462","https://orcid.org/0000-0003-4456-680X"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mengni He","raw_affiliation_strings":["1Yale,","Yale,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Yale,","institution_ids":["https://openalex.org/I32971472"]},{"raw_affiliation_string":"Yale,","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5096004690","display_name":"Revekka Khaimova","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Revekka Khaimova","raw_affiliation_strings":["2Alexion, AstraZeneca Rare Disease,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Alexion, AstraZeneca Rare Disease,","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Katherine Bates","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katherine Bates","raw_affiliation_strings":["3Yale School of Medicine,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Yale School of Medicine,","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046787323","display_name":"Nay Nwe Nyein Chan","orcid":"https://orcid.org/0009-0006-1633-6125","observed_orcids":["https://orcid.org/0009-0006-1633-6125"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nay Nwe Nyein Chan","raw_affiliation_strings":["4Yale School of Medicine, New Haven, Connecticut, United States,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Yale School of Medicine, New Haven, Connecticut, United States,","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071022580","display_name":"Daniel C. Liebler","orcid":"https://orcid.org/0000-0002-7873-3031","observed_orcids":["https://orcid.org/0000-0002-7873-3031"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel Liebler","raw_affiliation_strings":["5Inotiv, Inc.,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Inotiv, Inc.,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5134075329","display_name":"Regan S. Fulton","orcid":"https://orcid.org/0009-0004-5854-3451","observed_orcids":["https://orcid.org/0009-0004-5854-3451"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Regan Fulton","raw_affiliation_strings":["6Array Science, LLC,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Array Science, LLC,","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5027326018","display_name":"David L. Rimm","orcid":"https://orcid.org/0000-0001-5820-4397","observed_orcids":["https://orcid.org/0000-0001-5820-4397"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Rimm","raw_affiliation_strings":["7Yale University, New Haven, Connecticut, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Yale University, New Haven, Connecticut, United States","institution_ids":["https://openalex.org/I32971472"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"84","issue":"9_Supplement","first_page":"PO3","last_page":"13"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9585000276565552,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9585000276565552,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.029400000348687172,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.002099999925121665,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trop2","display_name":"TROP2","score":0.9440000057220459},{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.9319999814033508},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.8999999761581421},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9210000038146973},{"id":"https://openalex.org/keywords/sacituzumab-govitecan","display_name":"sacituzumab govitecan","score":0.9380000233650208},{"id":"https://openalex.org/keywords/trastuzumab-deruxtecan","display_name":"trastuzumab deruxtecan","score":0.9990000128746033},{"id":"https://openalex.org/keywords/quantitative-immunofluorescence","display_name":"quantitative immunofluorescence","score":0.8930000066757202},{"id":"https://openalex.org/keywords/multiplex-immunofluorescence","display_name":"multiplex immunofluorescence","score":0.8450000286102295},{"id":"https://openalex.org/keywords/patient-selection","display_name":"patient selection","score":0.7879999876022339},{"id":"https://openalex.org/keywords/her2-low-metastatic-breast-cancer","display_name":"HER2-low metastatic breast cancer","score":0.8320000171661377},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.9240000247955322},{"id":"https://openalex.org/keywords/hormone-receptor-positive-breast-cancer","display_name":"hormone receptor-positive breast cancer","score":0.8059999942779541},{"id":"https://openalex.org/keywords/cytokeratin","display_name":"cytokeratin","score":0.6600000262260437},{"id":"https://openalex.org/keywords/automated-image-analysis","display_name":"automated image analysis","score":0.46700000762939453}],"concepts":[{"id":"https://openalex.org/C2777325958","wikidata":"https://www.wikidata.org/wiki/Q1069596","display_name":"Antibody-drug conjugate","level":4,"score":0.7810726165771484},{"id":"https://openalex.org/C2778236600","wikidata":"https://www.wikidata.org/wiki/Q592324","display_name":"Immunofluorescence","level":3,"score":0.7513775825500488},{"id":"https://openalex.org/C2781188995","wikidata":"https://www.wikidata.org/wiki/Q6934982","display_name":"Multiplex","level":2,"score":0.7158119678497314},{"id":"https://openalex.org/C197336794","wikidata":"https://www.wikidata.org/wiki/Q5161150","display_name":"Conjugate","level":2,"score":0.6396547555923462},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.6152321100234985},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.6025794148445129},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5292569994926453},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4975426495075226},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4514233469963074},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.44051486253738403},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.432861328125},{"id":"https://openalex.org/C81917197","wikidata":"https://www.wikidata.org/wiki/Q628760","display_name":"Selection (genetic algorithm)","level":2,"score":0.4300258159637451},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.3942831754684448},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.29093560576438904},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2748323678970337},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.25078266859054565},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.17074227333068848},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.1473667323589325},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.14427050948143005},{"id":"https://openalex.org/C134306372","wikidata":"https://www.wikidata.org/wiki/Q7754","display_name":"Mathematical analysis","level":1,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C154945302","wikidata":"https://www.wikidata.org/wiki/Q11660","display_name":"Artificial intelligence","level":1,"score":0.0},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs23-po3-13-11","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po3-13-11","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs23-po3-13-11","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4412484841","https://openalex.org/W7130720695","https://openalex.org/W4411287182","https://openalex.org/W4416114599","https://openalex.org/W7129190590","https://openalex.org/W7130503309","https://openalex.org/W7130046842","https://openalex.org/W4396587776","https://openalex.org/W4362592901","https://openalex.org/W4362542739"],"abstract_inverted_index":{"Abstract":[0],"Emerging":[1],"antibody":[2],"drug":[3],"conjugate":[4],"(ADC)":[5],"therapies":[6,69],"targeting":[7],"human":[8,14],"trophoblast":[9],"cell-surface":[10],"antigen":[11,129],"(TROP2)":[12],"and":[13,32,54,63,109,127,152,166,188,194,206,224,251,271,292,326,340,380,402,412,432,435,439,454,470,486,501,520,551],"epidermal":[15],"growth":[16],"factor":[17],"receptor":[18,50],"2":[19],"(HER2)":[20],"are":[21,81,97,116],"transforming":[22],"the":[23,58,103,107,110,363,375,395,400,416,458,472,475,570],"treatment":[24,64],"landscape":[25],"for":[26,39,66,87,135,142,182,217,244,452,466,549,561],"breast":[27,46,207,268,316,345,493,510],"cancer.":[28],"Sacituzumab":[29],"govitecan":[30],"(SG)":[31],"trastuzumab":[33],"deruxtecan":[34],"(T-DXd)":[35],"have":[36],"gained":[37],"approval":[38],"an":[40,239],"overlapping":[41],"set":[42],"of":[43,61,105,125,267,365,370,377,385,391,407,420,474,499,513,569],"\"HER2-low\"":[44],"metastatic":[45],"cancers,":[47],"including":[48],"hormone":[49],"(HR)-positive":[51],"HER2":[52,91,128,252,293,303,327,341,405,413,438,485,500,519,552],"non-amplified":[53],"\"triple-negative\"":[55],"subtypes.":[56],"Nevertheless,":[57],"optimal":[59],"selection":[60,141,469],"patients":[62],"sequencing":[65],"these":[67],"ADC":[68,143,467,481],"remains":[70],"a":[71,148,161,278,334,381,403,462],"clinical":[72,330,463],"challenge.":[73],"Clinical":[74],"trial":[75],"objective":[76],"response":[77,456],"rates":[78],"to":[79,85,99,113,177,196,311,322,447,460,477,482],"SG":[80,455],"approximately":[82],"30%,":[83],"compared":[84],"30-90%":[86],"T-DXd":[88,453],"depending":[89],"on":[90,200],"expression":[92,130,328,342,359,384,406,450,489,504],"levels.":[93],"While":[94],"both":[95],"drugs":[96],"thought":[98],"be":[100],"targeted":[101],"therapies,":[102],"value":[104,473],"measuring":[106],"target":[108],"best":[111],"methods":[112],"do":[114],"so":[115],"still":[117],"not":[118],"established.":[119],"We":[120,232,305,332,427],"believe":[121],"that":[122],"quantitative":[123,155],"measurement":[124],"TROP2":[126,250,279,290,325,339,358,383,411,431,487,502,521,550],"levels":[131,360,505],"could":[132],"establish":[133],"thresholds":[134,451],"responders,":[136],"enabling":[137],"more":[138],"effective":[139],"patient":[140,468],"therapies.":[144],"Here,":[145],"we":[146,170,423],"present":[147],"TROP2,":[149],"high-sensitivity":[150,518],"HER2,":[151,389],"cytokeratin":[153],"(CK)":[154],"immunofluorescence":[156],"(QIF)":[157],"multiplex":[158,213,309,522],"assay.":[159],"Using":[160],"ten-cell":[162],"line":[163,203],"standard":[164,204,273],"array":[165,205],"proteomic":[167],"mass":[168],"spectrometry,":[169],"can":[171],"convert":[172],"tumor":[173],"compartment":[174],"QIF":[175,253],"intensity":[176],"protein":[178,488,503],"concentration":[179],"in":[180,236,343,368,418,491,506,554],"fmol/mm2":[181,286,300],"tissue":[183,209],"specimens.":[184],"Anti-HER2,":[185],"anti-TROP2":[186],"antibodies,":[187],"fluorescence":[189,225],"detection":[190,366],"systems":[191],"were":[192,361,393,414,433,440],"titrated":[193],"combined":[195],"maximize":[197],"signal-to-noise":[198],"ratio":[199],"our":[201,234,344,517],"cell":[202,272],"cancer":[208,269,317,346,494,511],"microarrays":[210],"(TMA).":[211],"The":[212],"assay":[214,276,310,465,476,524],"was":[215,258],"designed":[216],"automated":[218,245],"slide":[219,226],"stainers":[220],"(Leica":[221],"BOND":[222],"Rx)":[223],"scanning":[227],"(Rarecyte":[228],"CyteFinder":[229],"II":[230],"HT).":[231],"perform":[233],"analyses":[235],"QuPath":[237],"using":[238,264,516],"image":[240],"processing":[241],"plugin":[242],"developed":[243],"QIF/IHC":[246],"analysis":[247],"(Qymia).":[248],"Reproducible":[249],"scoring":[254],"(R\u00b2":[255],">":[256],"0.95)":[257],"achieved":[259],"across":[260],"multiple":[261],"staining":[262],"batches":[263],"serial":[265,313,507],"sections":[266],"TMAs":[270],"arrays.":[274],"This":[275],"has":[277],"linear":[280,294],"range":[281,295],"between":[282,296,338],"0.63":[283],"-":[284,298],"9.17":[285],"(about":[287,301],"1":[288],"million":[289],"receptors/cell)":[291],"0.09":[297],"0.565":[299],"60,000":[302],"receptors/cell).":[304],"then":[306],"applied":[307],"this":[308],"two":[312],"retrospective":[314,508],"primary":[315,509],"cohorts":[318,347],"from":[319],"Yale":[320,492],"University":[321],"quantitatively":[323,448],"measure":[324],"(338":[329],"cases).":[331],"find":[333],"weak":[335],"negative":[336],"correlation":[337],"(Pearson":[348],"r":[349],"=":[350,353,356],"-0.14,":[351],"p":[352],"0.0097,":[354],"n":[355],"338).":[357],"above":[362,394],"limit":[364,376],"(LOD)":[367],"90.2%":[369],"cases,":[371,421],"with":[372,397,457],"4.1%":[373],"exceeding":[374,399],"linearity":[378],"(LOL),":[379],"mean":[382,404],"4.05":[386],"fmol/mm2.":[387,409],"For":[388],"67.2%":[390],"cases":[392,515],"LOD,":[396],"7.1%":[398],"LOL,":[401],"0.186":[408],"Both":[410],"below":[415],"LOD":[417],"3.0%":[419],"which":[422,480],"define":[424,449],"as":[425],"\u201cnegative\u201d.":[426],"found":[428],"29.9%":[429],"expressed":[430,437],"HER2-negative,":[434],"6.8%":[436],"TROP2-negative.":[441],"Our":[442],"future":[443],"studies":[444],"will":[445],"aim":[446],"goal":[459],"produce":[461],"grade":[464],"determine":[471],"help":[478],"select":[479],"give":[483],"first.":[484],"summary":[490],"cohort":[495,512],"Table":[496],"1:":[497],"Summary":[498],"338":[514],"immunofluorescent":[523],"Citation":[525],"Format:":[526],"Charles":[527],"Robbins,":[528],"Mengni":[529],"He,":[530],"Revekka":[531],"Khaimova,":[532],"Katherine":[533],"Bates,":[534],"Nay":[535],"Nwe":[536],"Nyein":[537],"Chan,":[538],"Daniel":[539],"Liebler,":[540],"Regan":[541],"Fulton,":[542],"David":[543],"Rimm.":[544],"Quantitative":[545],"Multiplex":[546],"Immunofluorescence":[547],"Assay":[548],"Expression":[553],"Breast":[555,574],"Cancer:":[556],"Towards":[557],"Guiding":[558],"Patient":[559],"Selection":[560],"Antibody":[562],"Drug":[563],"Conjugate":[564],"Therapies":[565],"[abstract].":[566],"In:":[567],"Proceedings":[568],"2023":[571,577],"San":[572,580],"Antonio":[573],"Cancer":[575,586],"Symposium;":[576],"Dec":[578],"5-9;":[579],"Antonio,":[581],"TX.":[582],"Philadelphia":[583],"(PA):":[584],"AACR;":[585],"Res":[587],"2024;84(9":[588],"Suppl):Abstract":[589],"nr":[590],"PO3-13-11.":[591]},"counts_by_year":[{"year":2025,"cited_by_count":3}],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2024-05-03T00:00:00"}